Analysis of results heterogeneity of NOACs vs warfarin.
收藏Figshare2015-12-02 更新2026-04-29 收录
下载链接：
https://figshare.com/articles/dataset/_Analysis_of_results_heterogeneity_of_NOACs_vs_warfarin_/1185174
下载链接
链接失效反馈官方服务：
资源简介：
Given are the main results (including all dosages or the dose with most pronounced efficacy result)* and grouping by regimen (BID or QD) are displayed. BID, twice-daily dosing; FEM, fixed-effects meta-analysis; NOACs, novel oral anticoagulants; QD, once-daily dosing.Note. Bold font marks nearly absence of heterogeneity, i.e., generation of a common estimate is justified.*Dose with most pronounced efficacy result: dabigatran 150 mg BID, apixaban 5/2.5 mg BID, rivaroxaban 20/15 mg QD, and edoxaban 60/30 mg QD.Analysis of results heterogeneity of NOACs vs warfarin.
创建时间：
2015-12-02
